Pfizer Inc
featured
Stocks closed down 1 percent after the minutes from the last Fed policy setting meeting suggested the central bank could begin tapering bond purchases sooner than the market expects.
» Read More
More
-
Baxter International Inc. fell$. 64 or. 9 percent, to $71.51. Bristol-Myers Squibb Co. rose$. 40 or. 9 percent, to $47.40. Hospira fell$. 10 or. 3 percent, to $35.08.
-
Baxter International Inc. fell$. 48 or. 7 percent, to $71.67. Bristol-Myers Squibb Co. fell$. 25 or. 5 percent, to $46.75. Hospira fell$. 09 or. 3 percent, to $35.09.
-
NEW YORK-- A look at New York Stock Exchange 10 most-active stocks at 1 p.m.:. Advanced Micro Devices Inc. rose. 1 percent to $4.01 with 12,944,700 shares traded. Bank of America Corp. fell. 4 percent to $13.16 with 52,114,000 shares traded.
-
Baxter International Inc. fell$. 72 or 1.0 percent, to $71.43. Bristol-Myers Squibb Co. fell$. 31 or. 7 percent, to $46.69. Hospira fell$. 20 or. 6 percent, to $34.98.
-
Baxter International Inc. fell$. 15 or. 2 percent, to $72.15. Bristol-Myers Squibb Co. rose$. 60 or 1.3 percent, to $47.00. Hospira fell$. 22 or. 6 percent, to $35.18.
-
Baxter International Inc. fell$. 60 or. 8 percent, to $71.70. Bristol-Myers Squibb Co. rose$. 36 or. 8 percent, to $46.76. Hospira fell$. 22 or. 6 percent, to $35.18.
-
NEW YORK-- A look at New York Stock Exchange 10 most-active stocks at 1 p.m.:. Advanced Micro Devices Inc. rose 1.3 percent to $4.01 with 23,755,300 shares traded. Bank of America Corp. fell. 3 percent to $13.27 with 122,899,600 shares traded.
-
Baxter International Inc. fell$. 58 or. 8 percent, to $71.72. Bristol-Myers Squibb Co. fell$. 21 or. 5 percent, to $46.19. Hospira fell$. 26 or. 7 percent, to $35.14.
-
CHICAGO, May 23- Kathrin Jansen is a microbiologist with at least two breakthrough vaccines to her name: she brought the cervical cancer vaccine Gardasil to market for Merck and helped develop the $4 billion a year pneumonia and meningitis vaccine Prevnar 13 for Pfizer.
-
Baxter International Inc. fell$. 74 or 1.0 percent, to $72.30. Bristol-Myers Squibb Co. rose $2.34 or 5.3 percent, to $46.40. Hospira fell$. 52 or 1.4 percent, to $35.40.
-
Stocks closed down 1 percent after the minutes from the last Fed policy setting meeting suggested the central bank could begin tapering bond purchases sooner than the market expects.
-
Baxter International Inc. rose$. 16 or. 2 percent, to $73.20. Bristol-Myers Squibb Co. rose $3.30 or 7.5 percent, to $47.36. Hospira rose$. 02 or. 1 percent, to $35.94.
-
NEW YORK-- A look at New York Stock Exchange 10 most-active stocks at 1 p.m.:. Bank of America Corp. rose 1.4 percent to $13.63 with 88,111,200 shares traded. Barrick Gold Corp. rose 1.8 percent to $19.71 with 16,112,200 shares traded.
-
Baxter International Inc. rose$. 32 or. 4 percent, to $73.36. Bristol-Myers Squibb Co. rose $2.27 or 5.2 percent, to $46.33. Hospira rose$. 21 or. 6 percent, to $36.13.
-
TRENTON, N.J.-- Drugmaker Pfizer Inc. plans to try to sell its controlling stake in its former animal health business, Zoetis Inc., through a voluntary stock exchange with Pfizer shareholders.
-
May 22- Pfizer Inc said on Wednesday it will spin off its majority stake in animal health business Zoetis Inc to shareholders by allowing them to swap Pfizer stock for Zoetis stock at a 7 percent discount. Pfizer, the largest U.S. drugmaker, sold Zoetis shares in an initial public offering in February that raised $2.2 billion.
-
May 22- Pfizer Inc said on Wednesday that it would unwind its remaining stake in animal health business Zoetis Inc through an exchange offer in which shareholders can swap Pfizer stock for that of Zoetis at a discount. Giant pharmaceutical maker Pfizer spun off Zoetis shares in an initial public offering in February that raised $2.2 billion.
-
Baxter International Inc. rose$. 10 or. 1 percent, to $73.04. Bristol-Myers Squibb Co. rose$. 30 or. 7 percent, to $44.06. Hospira fell$. 11 or. 3 percent, to $35.92.
-
Stocks closed higher but off their best levels after two Fed officials dampened speculation the central bank was ready to consider "tapering" its bond-buying.
-
In a story May 20 about Pfizer Inc. halting a cancer drug study, The Associated Press erroneously reported the uses of two of the drugmaker's existing cancer medicines. Bosulif is approved for use in certain patients with chronic myelogenous leukemia and Inlyta is for advanced kidney cancer.